ATE238689T1 - ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT - Google Patents

ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT

Info

Publication number
ATE238689T1
ATE238689T1 AT00958855T AT00958855T ATE238689T1 AT E238689 T1 ATE238689 T1 AT E238689T1 AT 00958855 T AT00958855 T AT 00958855T AT 00958855 T AT00958855 T AT 00958855T AT E238689 T1 ATE238689 T1 AT E238689T1
Authority
AT
Austria
Prior art keywords
alpha
physiologically acceptable
intestinal absorption
amylase inhibitor
ßfast
Prior art date
Application number
AT00958855T
Other languages
English (en)
Inventor
Nils Christian Mortensen
Original Assignee
Med Eq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Eq As filed Critical Med Eq As
Application granted granted Critical
Publication of ATE238689T1 publication Critical patent/ATE238689T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00958855T 1999-09-08 2000-09-08 ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT ATE238689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (1)

Publication Number Publication Date
ATE238689T1 true ATE238689T1 (de) 2003-05-15

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958855T ATE238689T1 (de) 1999-09-08 2000-09-08 ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT

Country Status (14)

Country Link
EP (1) EP1213972B1 (de)
JP (1) JP2003508467A (de)
KR (1) KR100594520B1 (de)
AT (1) ATE238689T1 (de)
AU (1) AU777044B2 (de)
CA (1) CA2383720A1 (de)
DE (1) DE60002484T2 (de)
DK (1) DK1213972T3 (de)
ES (1) ES2199174T3 (de)
GB (2) GB9921229D0 (de)
NO (1) NO314922B1 (de)
NZ (1) NZ518167A (de)
PT (1) PT1213972E (de)
WO (1) WO2001017369A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
ITMI20052450A1 (it) * 2005-12-22 2007-06-23 Indena Spa Estratti di phaseolus vulgaris loro uso e formulazioni che li contengono
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス
US20100330137A1 (en) * 2008-03-10 2010-12-30 Mauro Mantovani High bioavailability formulation of mangosteen and manufacturing process thereof
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
EP3193899A1 (de) * 2014-09-19 2017-07-26 Nestec S.A. Verfahren und formulierungen zur senkung der resorption der kohlenhydrate in ein haustier
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.
EP3975755A1 (de) * 2019-05-24 2022-04-06 Cosucra Groupe Warcoing S.A. Zusammensetzung mit inulin und protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
JP2002535288A (ja) * 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ．ア．エッセ． リポタンパク質複合体およびそれらを含む組成物

Also Published As

Publication number Publication date
NO314922B1 (no) 2003-06-16
AU7026900A (en) 2001-04-10
KR100594520B1 (ko) 2006-07-19
GB2364498A (en) 2002-01-30
PT1213972E (pt) 2003-09-30
AU777044B2 (en) 2004-09-30
DE60002484D1 (de) 2003-06-05
NZ518167A (en) 2003-03-28
CA2383720A1 (en) 2001-03-15
ES2199174T3 (es) 2004-02-16
NO20021160L (no) 2002-03-27
EP1213972A1 (de) 2002-06-19
JP2003508467A (ja) 2003-03-04
KR20020045605A (ko) 2002-06-19
DK1213972T3 (da) 2003-08-18
GB9921229D0 (en) 1999-11-10
EP1213972B1 (de) 2003-05-02
NO20021160D0 (no) 2002-03-08
WO2001017369A1 (en) 2001-03-15
GB0127158D0 (en) 2002-01-02
DE60002484T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60002484D1 (de) Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält
DE69226624D1 (de) Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
CA2186380A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
TR200000785T2 (tr) Yeni NPY antagonistleri.
HK1039745A1 (zh) 用於改善识别的非典型抗精神病药和乙酰胆碱酯酶
AU3109502A (en) Method and composition for the treatment of diabetic neuropathy
AU2003295866A1 (en) Effervescent compositions
WO2003086271A3 (en) Azole derivatives as antifungal agents
EP1068868A3 (de) Synergistischer Zusammensetzung, der Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeneration
NO990813L (no) Forlegering for kornforfining av aluminiumslegeringer
MX2024014831A (es) Derivados de acido sialico y metodos de uso de los mismos
GB9819317D0 (en) Organic compounds
ATE335409T1 (de) Suesstoffzusammensetzung
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
GB2412066A (en) Method of reducing toxicity of anticancer agents
PL357078A1 (en) A method for maintaining or improving the synthesis of mucins
YU58102A (sh) Postupak za održavanje ili poboljšanje sinteze mucina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1213972

Country of ref document: EP

REN Ceased due to non-payment of the annual fee